Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator’s choice chemotherapy following progression on afatinib monotherapy.
Martin H. Schuler
Consultant or Advisory Role - Boehringer Ingelheim
Research Funding - Boehringer Ingelheim; Roche
David Planchard
Honoraria - Boehringer Ingelheim
James Chih-Hsin Yang
Consultant or Advisory Role - Boehringer Ingelheim (U)
Honoraria - Boehringer Ingelheim
Joo-Hang Kim
Research Funding - Boehringer Ingelheim
Filippo De Marinis
No relevant relationships to disclose
Yuh-Min Chen
No relevant relationships to disclose
Caicun Zhou
No relevant relationships to disclose
Jaafar Bennouna
Consultant or Advisory Role - Amgen
Honoraria - Boehringer Ingelheim; Roche
Xiaoqing Liu
No relevant relationships to disclose
Ji Feng Feng
No relevant relationships to disclose
Paolo Bidoli
No relevant relationships to disclose
Janos Strausz
No relevant relationships to disclose
Sai-Hong Ignatius Ou
No relevant relationships to disclose
Vikram K. Chand
Employment or Leadership Position - Boehringer Ingelheim
Bushi Wang
Employment or Leadership Position - Boehringer Ingelheim
Gerd Michael Munzert
Employment or Leadership Position - Boehringer Ingelheim
Keunchil Park
Consultant or Advisory Role - Boehringer Ingelheim